Market cap
₹8,731 Cr
Recently Viewed
Clear AllNSE: AKUMS | BSE: 544222
₹556.70
₹3.90
(0.71%)
As on 06-May-2026 13:24IST
Market cap
₹8,731 Cr
Revenue (TTM)
₹4,257 Cr
P/E Ratio
27.4
P/B Ratio
2.7
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹318 Cr
ROE
18.3 %
ROCE
17.8 %
Industry P/E
57.56
EV/EBITDA
12.3
Debt to Equity
0
Book Value
₹204.4
EPS
₹20
Face value
2
Shares outstanding
157,393,988
CFO
₹1,685.27 Cr
EBITDA
₹1,971.15 Cr
Net Profit
₹657.21 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akums Drugs And Pharmaceuticals
| 22.8 | 11.6 | 24.4 | 7.1 | -- | -- | -- |
|
BSE Healthcare
| 6.7 | 12.0 | 9.9 | 9.3 | 26.1 | 14.0 | 11.6 |
|
Company
|
2025
|
|---|---|
|
Akums Drugs And Pharmaceuticals
| -28.4 |
|
BSE Small Cap
| -6.6 |
|
BSE Healthcare
| -3.3 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akums Drugs And Pharmaceuticals
|
556.7 | 8,730.6 | 4,256.7 | 324.7 | 7.3 | 10.1 | 27.4 | 2.7 |
| 2,704.4 | 22,346.7 | 1,339.4 | 356.4 | 33.2 | 23.2 | 62.7 | 13.5 | |
| 787.1 | 15,273.0 | 7,266.8 | 627.5 | 11.9 | 12.6 | 24.3 | 2.8 | |
| 482.8 | 18,445.5 | 2,051.5 | 180.5 | 11.6 | 7.7 | 91.5 | 4.8 | |
| 745.6 | 18,448.5 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31 | 3.6 | |
| 1,168.5 | 20,884.2 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13.4 | 2.4 | |
| 1,739.0 | 19,912.9 | 1,419.3 | 20.1 | 8.4 | 0.5 | 990.6 | 3.4 | |
| 165.1 | 21,793.0 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.7 | |
| 447.9 | 18,122.7 | 3,738.7 | 316.7 | 12.5 | 7.5 | 57.2 | 3.7 | |
| 1,766.3 | 28,197.3 | 3,373.0 | 199.0 | 12.6 | 5.9 | 132.4 | 5.7 |
5 min read•By Hemkesh Khattar
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It offers dosage forms, such as tablets, hard and soft gelatin capsules, liquid orals, sachets,... vials, ampoules, form fill seals, topical preparations, eye drops, dry powder injections, rotacaps and gummies, and others. The company operates as pharmaceutical contract development and manufacturing company. It also sells branded pharmaceutical formulations. The company was incorporated in 2004 and is based in Delhi, India. Read more
Incorporated
2004
Chairman
--
Managing Director
Sanjeev Jain
Headquarters
Delhi, Delhi
Website
Looking for more details about Akums Drugs And Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Akums Drugs And Pharmaceuticals Ltd is ₹556.70 (NSE) and ₹558.00 (BSE) as of 06-May-2026 13:24 IST. Akums Drugs And Pharmaceuticals Ltd has given a return of 7.09% in the last 1 years.
The P/E ratio of Akums Drugs And Pharmaceuticals Ltd is 27.44 times as on 06-May-2026, a 52 discount to its peers’ median range of 57.56 times.
The P/B ratio of Akums Drugs And Pharmaceuticals Ltd is 2.71 times as on 06-May-2026, a 22 discount to its peers’ median range of 3.47 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
21.49
|
2.38
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Akums Drugs And Pharmaceuticals Ltd are Rs 622.95 and Rs 409.30 as of 06-May-2026.
Akums Drugs And Pharmaceuticals Ltd has a market capitalisation of ₹ 8,731 Cr as on 06-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Akums Drugs And Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.